Special Meeting To Be Held on April 21, 2017 SAN DIEGO, CA and AUSTIN, TX – March 16, 2017 – Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today it has… read more →
Proposed Merger Creates Specialty Pharmaceutical Company with Three Clinical-Stage Inhaled Product Candidates for Serious and Life-Threatening Diseases Conference Call Scheduled for Monday, January 9 at 8:30 a.m. ET / 5:30… read more →
Austin, Texas – November 2, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced the company has appointed David L. Lowrance, CPA, as… read more →
Strengthens pipeline serving patients with rare respiratory diseases Austin, Texas – July 18, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced the… read more →
Adds two orphan respiratory drugs to its growing pipeline Austin, Texas – June 21, 2016 Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced that… read more →
New York City – June 9, 2016 Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced that the company will present at the Jefferies 2016… read more →
Savara’s phase II/III clinical trial of lead drug candidate Molgradex® for patients with pulmonary alveolar proteinosis (PAP) has included its first patient. The patient has been dosed with Savara’s proprietary,… read more →
Savara signs license agreement with Japanese Nobelpharma Co. Ltd for future commercialisation of Molgradex® in Japan. With reference to earlier company notice from 18.12.2015, a definitive license agreement has now… read more →
Preparation underway for Phase 3 trial of AeroVanc for MRSA lung infection in people with cystic fibrosis Austin, TX – March 1, 2016 Savara Pharmaceuticals announced today that it has… read more →
Trial also demonstrates strong trends in secondary clinical endpoints Austin, TX – February 23, 2015 Savara Pharmaceuticals announced today positive topline results from its Phase 2 clinical trial of AeroVanc,… read more →
